Skip to main content
Genomic Vision logo

Genomic Vision — Investor Relations & Filings

Ticker · GV ISIN · FR0011799907 LEI · 969500UXJNBY1C8Y8471 PA Professional, scientific and technical activities
Open in API
Filings indexed 412 across all filing types
Latest filing 2023-04-25 Declaration of Voting R…
Country FR France
Listing PA GV

About Genomic Vision

https://www.genomicvision.com/

Genomic Vision is a biotechnology company specializing in the direct visualization and analysis of single DNA molecules through its proprietary Molecular Combing technology. This platform provides highly accurate characterization of large-scale genomic modifications, offering critical insights into genetic integrity and stability. The company's primary focus is on providing quality control (QC) solutions for the bioproduction and cell and gene therapy markets, ensuring the safety and efficacy of advanced therapeutic products. In drug discovery, its Replication Combing Assay (RCA) is used to assess the effects of compounds on DNA replication. Genomic Vision's tools and services support the entire lifecycle of biopharmaceutical development, from research to production.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document explicitly states it is a 'Déclaration au titre de l'article 223-16 du règlement général de l'Autorité des marchés financiers' (Declaration under Article 223-16 of the General Regulation of the AMF) and provides the total number of shares and voting rights as of a specific date (24.04.2023). This structure, focusing on the total share capital and voting rights calculation basis, is characteristic of regulatory filings related to share structure transparency, often required when crossing ownership thresholds or for general disclosure. While it relates to share capital, it is not a formal share issue announcement (SHA) or a transaction in own shares (POS). It is a mandatory regulatory disclosure regarding the capital structure and voting rights base. Given the options, this specific type of regulatory disclosure about the total number of shares and voting rights, which is often triggered by ownership changes or required periodically, fits best under the general 'Regulatory Filings' (RNS) category, as there is no specific code for 'Total Voting Rights Disclosure'. It is not an AGM-R, 10-K, ER, or IR. It is a formal regulatory statement.
2023-04-25 French
Inside Information / News release on accounts, results
Earnings Release Classification · 100% confidence The document is a press release titled '2022 ANNUAL RESULTS' issued by Genomic Vision. It provides a summary of financial performance (revenues, operating loss, net loss), discusses business strategy, financing, and governance changes. It is an initial announcement of financial results rather than the full audited Annual Report (which it explicitly mentions will be provided in a separate URD document). Therefore, it fits the definition of an Earnings Release (ER). FY 2022
2023-04-20 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 98% confidence The document is titled "RÉSULTATS ANNUELS 2022" (Annual Results 2022) and contains a detailed table of IFRS financial results for the years 2022 and 2021, including revenue, operating expenses, and net result. It discusses operational performance, financial structure (cash, financing line with Winance), and governance changes following a general meeting. This content strongly indicates a comprehensive report of annual financial performance. Although it mentions the final Universal Registration Document (URD) will be available later, the text itself is the detailed release of the annual financial figures. This aligns best with the Annual Report (10-K) definition, which covers full yearly financial performance, even if this specific document might be a press release summarizing the 10-K content, it is far more detailed than a simple Earnings Release (ER) and covers the full year, making 10-K the most appropriate classification for the underlying content type being reported, or IR (Interim/Quarterly Report) if it were a half-year report, but since it explicitly states 'Résultats Annuels 2022', 10-K is the closest fit among the options for a full-year financial disclosure. However, the text explicitly states: "Le document d'enregistrement universel, incluant le rapport financier annuel, sera disponible dans les délais légaux." and also mentions the upcoming availability of the URD 2022 on April 27, 2023. This suggests the provided text is the press release announcing the results, not the final, filed 10-K document itself. Given the detailed financial tables and full-year scope, it is a comprehensive financial disclosure. If it were a simple announcement of the report release, it would be RPA or RNS. Since it contains the actual detailed results, it functions as the primary financial disclosure for the period. In the context of US SEC filings, this would be the 10-K content. For non-US filings that provide full annual results in a press release format, the closest fit is often 10-K or IR. Since it is annual, 10-K is chosen over IR. If the document were significantly shorter and only pointed to the attached report, RPA would be better. Since it contains the core data, 10-K is selected. FY 2022
2023-04-20 French
Inside Information / Other news releases
Regulatory Filings Classification · 100% confidence The document is a press release announcing that Genomic Vision has joined the France BioLead Association. It details the purpose of the association and the company's role within it, focusing on strategy and industry participation. This type of announcement, which is not a formal financial report (like 10-K, IR, ER) but rather a corporate development update, fits best under the general 'Regulatory Filings' (RNS) category, as it is a public announcement of a non-financial strategic event. It does not fit the specific definitions for AGM-R, 10-K, AR, MANG, CT, CAP, DVA, DLST, DIRS, ER, SR, XLSX, FS, CGR, IRAT, IR, IP, LTR, TAR, MRQ, MDA, NAV, DIV, PSI, DEF 14A, RPA, SHA, or POS. Since it is a general corporate announcement, RNS is the appropriate fallback.
2023-04-03 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 100% confidence The document is a press release announcing that Genomic Vision has joined the 'France BioLead' association to focus on bioproduction innovation. It details the strategic shift, the goals of the association, and includes commentary from the Chairman of the Management Board. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is an announcement concerning company strategy and industry participation. Since it is a general corporate announcement that doesn't fit the specific categories like M&A (TAR), Capital Change (CAP), or Director's Dealing (DIRS), it falls best under the general 'Regulatory Filings' (RNS) category, which serves as a broad category for official corporate news releases that are not otherwise specified, or potentially a general 'LTR' if it were a legal/regulatory update, but this is a strategic partnership announcement. Given the options, RNS is the most appropriate fallback for a general, non-financial-result-focused corporate announcement.
2023-04-03 French
Informations privilégiées / Autres communiqués
Declaration of Voting Results & Voting Rights Announcements Classification · 99% confidence The document explicitly states it is a 'Déclaration au titre de l'article 223-16 du règlement général de l'Autorité des marchés financiers' (Declaration under Article 223-16 of the General Regulation of the AMF) and provides the total number of shares and theoretical gross voting rights as of a specific date (10.03.2023). This type of filing, detailing share capital structure and voting rights, is a mandatory regulatory disclosure in France. While it relates to capital structure, it is specifically about the total count of shares and voting rights, which is often reported separately from general capital changes (SHA) or major shareholding notifications (MRQ). Given the specific regulatory reference (AMF Article 223-16) and the content focusing purely on the capital denominator for threshold crossing calculations, it fits best under a general regulatory disclosure category. Since there is no specific code for 'Share Capital/Voting Rights Disclosure', and it is a formal regulatory filing, 'RNS' (Regulatory Filings) is the most appropriate fallback, although 'SHA' (Share Issue/Capital Change) is related, this document is a periodic statement of the denominator, not an issuance event. Given the context of mandatory regulatory reporting, RNS is chosen as the best fit among the provided options for a specific regulatory disclosure not covered by other codes.
2023-03-10 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.